Year None20232022202120202019201820172016 August 1, 2023 Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology Go to July 28, 2023 Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights Go to July 25, 2023 Medicenna Presents at National Brain Tumor Society's Research Round Table Go to July 5, 2023 Medicenna Extends Period to Exercise Certain Warrants Go to June 27, 2023 Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights Go to April 27, 2023 Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement Go to Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Next page next › Last page last »
August 1, 2023 Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology Go to
July 28, 2023 Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights Go to
April 27, 2023 Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement Go to
